The response to linsitinib is inferior to the topoisomerase inhibitor topotecan, with median progression-free survival of 3.0 (95% CI 1.53.6) and 1.2 (95% CI 1.11.4) months for topotecan and linsitinib, respectively [159]
doi:10.1016/j.jpsychores.2010.03.010
Browse Collection Liquid Research Sprays Precision-crafted liquid research materials designed for exceptional quality, consistency, and convenience
Meal Composition What you eat affects how long you stay full
This article analyzes the complete clinical dataset: Phase 2 results from 2023, TRIUMPH-4 Phase 3 data from December 2025, TRIUMPH-1 Phase 3 data from May 2026, TRANSCEND-T2D-1 data from June 2026, sleep apnea substudy results, safety profiles, and what the remaining TRIUMPH trials might reveal